Thromb Haemost 1985; 53(02): 225-227
DOI: 10.1055/s-0038-1661280
Original Article
Schattauer GmbH Stuttgart

The Effect of Platelet Number and Haematocrit on Whole Blood Thromboxane Synthesis

A J Carter
The Department of Medicine, University Hospital, Queen’s Medical Centre, Nottingham, UK
,
S P Hanley
The Department of Medicine, University Hospital, Queen’s Medical Centre, Nottingham, UK
› Author Affiliations
Further Information

Publication History

Received 26 November 1984

Accepted 09 January 1985

Publication Date:
18 July 2018 (online)

Summary

Whole blood, allowed to clot at 37° C in glass tubes, synthesized thromboxane A2 (TxA2) as determined by radioimmunoassay for thromboxane B2 (TxB2). The time course for TxB2 synthesis showed no further increase after 60 min and the concentration of TxB2 in serum obtained from 60 normal subjects positively correlated with the whole blood platelet count in EDTA anticoagulated blood from the same donor.

Patients with chronic renal failure produced less serum TxB2 than age- and sex-matched controls; they also had lower haematocrits. After re-calculating TxB2 production as a function of platelet count and haematocrit all but one of the patients fell in the range of values obtained for controls. These results suggest that chronic renal failure may not be associated with a cyclooxygenase defect and that clotted whole blood TxB2 production should be expressed as a function of platelet count and haematocrit.

 
  • References

  • 1 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sei USA 1974; 72: 2994-2998
  • 2 Goldstein IM, Malmsten CL, Kindahl H, Kaplan HB, Radmark O, Samuelsson B, Weissmann G. Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med 1978; 148: 787-792
  • 3 Morley J, Bray MA, Jones RW, Nugteren DH, van Dorp DA. Prostaglandin and thromboxane production by human and guinea-pig macrophages and leukocytes. Prostaglandins 1979; 17: 729-736
  • 4 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
  • 5 Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins Proc Natl Acad Sci USA 1974; 71: 3824-3828
  • 6 Pawlowski NA, Kaplan G, Hamill AL, Cohn ZA, Scott WA. Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures J Exp Med 1983; 158: 393-412
  • 7 Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day JS, Smith WL, Pinca E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uremia. Evidence for a cyclooxygenase defect J Clin Invest 1983; 71: 762-768
  • 8 Carter AJ, Bevan JA, Hanley SP, Morgan WE, Turner DR. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis - effect of thromboxane synthase inhibitor. Thromb Haemostas 1984; 51: 257-260
  • 9 Hall ER, Wu KK, O’Brien R. The reduction of potential TxB2 levels when serum is preincubated at room temperature. Prostaglandins Leukotrienes Med 1984; 13: 279-280